Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterization of CT Imaging-Derived Pulmonary Vascular Abnormalities Associated With Pulmonary Hypertension in Chronic Lung Disease.

Chest·2026
Same author

Holistic Management of Pulmonary Fibrosis: A Comprehensive Review.

Medicina (Kaunas, Lithuania)·2026
Same author

Optimizing line blot assays: impact of band intensity adjustment on diagnostic performance in myositis autoantibodies testing.

Clinical rheumatology·2026
Same author

Evaluation of particle-based multi-analyte technology for autoantibody detection in systemic sclerosis: concordance with conventional methods and clinical associations.

Clinical and experimental rheumatology·2026
Same author

Access to lymphangioleiomyomatosis care across Europe: an ERN-LUNG survey of clinical practice, and the case for a European registry and trial network.

ERJ open research·2026
Same author

Beyond inflammation: alarmins as critical drivers of pulmonary fibrosis.

ERJ open research·2026

Related Experiment Video

Updated: Jul 9, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Sarcoidosis: A Clinical Trials Perspective.

Juan J Zapata-Huizi1, Manuela Herrera-Tamayo1, Josmar J Ríos-Poveda1

  • 1Department of Respiratory Medicine, Respiratory Institute, Hospital Clinic de Barcelona, University of Barcelona, C/Villarroel 170, 08036, Barcelona, Spain.

Pulmonary Therapy
|July 8, 2026
PubMed
Summary

This review explores clinical trials for pulmonary sarcoidosis, highlighting limited evidence for current treatments like corticosteroids. Future directions include personalized medicine and collaborative trials for better disease management.

Keywords:
Clinical trialsCorticosteroidsImmunosuppressionInfliximabMethotrexatePREDMETHPulmonary sarcoidosisSARCORTSarcoidosisSteroid-sparing agents

More Related Videos

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

Related Experiment Videos

Last Updated: Jul 9, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

Area of Science:

  • Pulmonology
  • Immunology
  • Clinical Trials

Background:

  • Sarcoidosis is a systemic granulomatous disease with primary lung involvement.
  • Respiratory manifestations significantly contribute to sarcoidosis morbidity and mortality.
  • Current treatment evidence is limited, with corticosteroids as a common but not always evidence-based first-line therapy.

Purpose of the Study:

  • To review the current landscape of clinical trials for pulmonary sarcoidosis.
  • To emphasize landmark studies influencing contemporary treatment paradigms.
  • To propose future directions for pulmonary sarcoidosis treatment.

Main Methods:

  • Comprehensive literature review of clinical trials in pulmonary sarcoidosis.
  • Analysis of landmark studies and their impact on treatment.
  • Discussion of current treatment evidence and future research needs.

Main Results:

  • The evidence base for pulmonary sarcoidosis treatment is historically limited.
  • Corticosteroids are widely used but often based on observational data, not RCTs.
  • A need for more robust clinical trials and personalized medicine approaches is evident.

Conclusions:

  • Future pulmonary sarcoidosis treatment requires personalized medicine and validated biomarkers.
  • International collaborative trials are essential for advancing treatment paradigms.
  • Deeper understanding of pathophysiology may lead to disease-modifying therapies beyond symptom management.